Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00946699 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Tolerability of MEDI-551 in Scleroderma
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00946699 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 50 participants.
The verdict
NCT00946699, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-551 over escalating single doses in adult subjects with Scleroderma
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MEDI-551
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00946699
The ClinicalTrials.gov registry entry for NCT00946699 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00946699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00946699 about?
NCT00946699 is a clinical study titled "A Study of the Safety and Tolerability of MEDI-551 in Scleroderma". The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-551 over escalating single doses in adult subjects with Scleroderma
What is the current status of trial NCT00946699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2010-03. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00946699?
The interventions under investigation include: Placebo (BIOLOGICAL), MEDI-551 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00946699?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.